Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00291746 |
The primary objective of this study is to determine the accuracy of the Reflux Disease Questionnaire (RDQ) as a diagnostic test for gastroesophageal reflux disease. Symptom evaluation by the RDQ will be compared with other established approaches to the diagnosis of gastroesophageal reflux disease (GERD) in a primary care patient population with symptoms thought to be of upper gastrointestinal (GI) tract origin.
Condition | Intervention | Phase |
---|---|---|
Gastroesophageal Reflux |
Drug: Esomeprazole Procedure: Bravo technique |
Phase IV |
Study Type: | Interventional |
Study Design: | Diagnostic, Non-Randomized, Single Blind, Placebo Control, Single Group Assignment, Efficacy Study |
Official Title: | A Single-Blind Single Arm Study to Validate the Reflux Disease Questionnaire (RDQ) for the Diagnosis of Reflux Disease in Primary Care in Patients Treated With Esomeprazole 40 mg o.d. |
Estimated Enrollment: | 350 |
Study Start Date: | September 2005 |
Ages Eligible for Study: | 18 Years to 79 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Ontario | |
Research Site | |
Etobicoke, Ontario, Canada | |
Research Site | |
Hamilton, Ontario, Canada | |
Research Site | |
North York, Ontario, Canada | |
Canada, Quebec | |
Research Site | |
Saint-Leonard, Quebec, Canada | |
Research Site | |
Pointe-Claire, Quebec, Canada | |
Research Site | |
Saint-Jerome, Quebec, Canada | |
Research Site | |
Mirabel, Quebec, Canada | |
Denmark | |
Research Site | |
Glostrup, Denmark | |
Research Site | |
Herning, Denmark | |
Research Site | |
Odense, Denmark | |
Research Site | |
Randers, Denmark | |
Germany | |
Research Site | |
Garmisch-Partenkirchen, Germany | |
Research Site | |
Bochum, Germany | |
Research Site | |
Dresden, Germany | |
Research Site | |
Berlin, Germany | |
Research Site | |
Magdeburg, Germany | |
Research Site | |
München, Germany | |
Research Site | |
Siegen, Germany | |
Research Site | |
Halle, Germany | |
Research Site | |
Mainz, Germany | |
Research Site | |
Münster, Germany | |
Norway | |
Research Site | |
Bergen, Norway | |
Sweden | |
Research Site | |
Lund, Sweden | |
Research Site | |
Skövde, Sweden | |
Research Site | |
Stockholm, Sweden | |
Sweden, Västra Götaland | |
Research Site | |
Göteborg, Västra Götaland, Sweden | |
United Kingdom | |
Research Site | |
Coventry, United Kingdom | |
Research Site | |
Bicester, United Kingdom | |
Research Site | |
West Bromwich, United Kingdom | |
Research Site | |
London, United Kingdom |
Study Director: | AstraZeneca Nexium Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | D9914C00002, DIAMOND |
Study First Received: | February 14, 2006 |
Last Updated: | December 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00291746 |
Health Authority: | Norway: Norwegian Medicines Agency |
GERD |
Deglutition Disorders Esophageal Motility Disorders Digestive System Diseases Esophageal disorder |
Gastrointestinal Diseases Omeprazole Esophageal Diseases Gastroesophageal Reflux |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Ulcer Agents |
Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |